Other OTC - Delayed Quote USD

Panbela Therapeutics, Inc. (PBLA)

0.4100 -0.0300 (-6.82%)
At close: April 26 at 3:27 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
25,647.0000
25,647.0000
34,093.0000
10,010.0000
5,754.0000
Operating Income
-25,647.0000
-25,647.0000
-34,093.0000
-10,010.0000
-5,754.0000
Net Non Operating Interest Income Expense
-194.0000
-194.0000
-274.0000
-11.0000
-17.0000
Other Income Expense
392.0000
392.0000
-682.0000
-602.0000
708.0000
Pretax Income
-25,449.0000
-25,449.0000
-35,049.0000
-10,623.0000
-5,063.0000
Tax Provision
-186.0000
-186.0000
-116.0000
-488.0000
-295.0000
Net Income Common Stockholders
-25,263.0000
-25,263.0000
-34,933.0000
-10,135.0000
-4,768.0000
Diluted NI Available to Com Stockholders
-25,263.0000
-25,263.0000
-34,933.0000
-10,135.0000
-4,768.0000
Basic EPS
-157.02
-316.52
-19.97k
-18.10k
-11.86k
Diluted EPS
-157.02
-316.52
-19.97k
-18.10k
-11.86k
Basic Average Shares
149.8160
108.6910
1.7490
0.5600
0.4020
Diluted Average Shares
149.8160
108.6910
1.7490
0.5600
0.4020
Total Operating Income as Reported
-25,647.0000
-25,647.0000
-34,093.0000
-10,010.0000
-5,754.0000
Total Expenses
25,647.0000
25,647.0000
34,093.0000
10,010.0000
5,754.0000
Net Income from Continuing & Discontinued Operation
-25,263.0000
-25,263.0000
-34,933.0000
-10,135.0000
-4,768.0000
Normalized Income
-25,660.0400
-25,660.0400
-34,933.0000
-10,135.0000
-4,865.4380
Interest Income
123.0000
123.0000
14.0000
1.0000
--
Interest Expense
317.0000
317.0000
288.0000
12.0000
17.0000
Net Interest Income
-194.0000
-194.0000
-274.0000
-11.0000
-17.0000
EBIT
-25,132.0000
-25,132.0000
-34,761.0000
-10,611.0000
-5,046.0000
EBITDA
-25,132.0000
-25,132.0000
-34,761.0000
-10,611.0000
-5,046.0000
Net Income from Continuing Operation Net Minority Interest
-25,263.0000
-25,263.0000
-34,933.0000
-10,135.0000
-4,768.0000
Total Unusual Items Excluding Goodwill
400.0000
400.0000
--
--
103.0000
Total Unusual Items
400.0000
400.0000
--
--
103.0000
Normalized EBITDA
-25,532.0000
-25,532.0000
-34,761.0000
-10,611.0000
-5,149.0000
Tax Rate for Calcs
0.0000
0.0000
0.0000
0.0000
0.0001
Tax Effect of Unusual Items
2.9600
2.9600
--
--
5.5620
12/31/2020 - 1/3/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

RNAZ TransCode Therapeutics, Inc.
0.5499
+5.30%
 
CDIO Cardio Diagnostics Holdings, Inc.
0.6900
-4.49%
 
SPRC SciSparc Ltd.
1.3200
+4.76%
 
DRMA Dermata Therapeutics, Inc.
0.3427
-3.74%
 
NEXI NexImmune, Inc.
3.3700
-1.17%
 
ZVSA ZyVersa Therapeutics, Inc.
4.9900
-16.83%
 
ENSC Ensysce Biosciences, Inc.
0.5842
+1.69%
 
CING Cingulate Inc.
0.8801
+1.71%
 
PXMD PaxMedica, Inc.
0.7398
+5.06%
 
FWBI First Wave BioPharma, Inc.
2.7400
+0.37%